Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.

@article{Lotze1986ResultsOC,
  title={Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.},
  author={Michael T Lotze and Steven A Rosenberg},
  journal={Immunobiology},
  year={1986},
  volume={172 3-5},
  pages={420-37}
}
The administration of transferred lymphokine-activated killer (LAK) cells in conjunction with the administration of recombinant interleukin 2 (IL 2) at high doses has led to objective remissions in 14/41 cancer patients. Sequential studies with both Jurkat-derived IL 2, recombinant IL 2 and activated cells were conducted in a total of sixty-seven patients… CONTINUE READING